Human Trials

ACADIA announces top-line results from phase 3 schizophrenia trial of Pimavanserin

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), today announced top-line results from its Phase 3 ENHANCE study, which evaluated pimavanserin as an adjunctive treatment in adult schizophrenia patients with persistent inadequate response to their current antipsychotic therapy.

Sandoz recruits first patient in clinical study for proposed biosimilar denosumab in osteoporosis

Sandoz, a Novartis division and a global leader in biosimilars, announced the first patient enrolled in ROSALIA, an integrated Phase I/III clinical study for its proposed biosimilar denosumab.

Transgene receives MHRA approval for clinical trial of next-generation oncolytic virus

Transgene has received the approval from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) to proceed with a Phase 1/2a clinical trial of TG6002 administered by intrahepatic artery (IHA) infusion in colorectal cancer patients with unresectable liver metastases (CRLM).

GSK’s Zejula meets primary endpoint in phase 3 ovarian cancer trial

GlaxoSmithKline (GSK) said that a phase 3 trial evaluating its polymerase (PARP) inhibitor Zejula (niraparib) as a maintenance therapy for first-line ovarian cancer following platinum-based chemotherapy, has met its primary endpoint.

SOTIO initiates first-in-human clinical trial with IL-15 superagonist SO-C101

SOTIO and Cytune Pharma, members of the PPF Group, announce the first dosing of cancer patients with SO-C101, a superagonist fusion protein of interleukin IL-15.

Novartis, Amgen halt Alzheimer’s clinical programme with BACE1 inhibitor

Novartis, Amgen and Banner Alzheimer's Institute have decided to halt the clinical programme with BACE1 inhibitor CNP520 (umibecestat) for the prevention of Alzheimer's disease.

ViiV Healthcare’s phase 3 study of dolutegravir plus lamivudine meets primary endpoint

ViiV Healthcare, the global specialist HIV company majority-owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, today announced positive Week 48 results from its phase III TANGO study.

ViiV Healthcare begins study on implementation of once-monthly injectable HIV treatment

ViiV Healthcare has commenced a trial to identify and assess approaches for implementing its once-monthly injectable treatment for HIV into clinical practice.

Ipsen, Servier announce initial phase 1/2 data of liposomal irinotecan in metastatic pancreatic cancer

Ipsen and Servier announced preliminary data from the Phase 1/2 study of the investigational use of liposomal irinotecan (ONIVYDE) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in study patients with previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) at the ESMO 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, 3–6 July 2019.